Literature DB >> 8549731

A unique pattern of apo(a) polymorphism in an isolated east Greenlandic Inuit (Eskimo) population.

I C Klausen1, P S Hansen, J V Povlsen, L U Gerdes, L Lemming, O Faergeman.   

Abstract

Eskimos of the east coast of Greenland very rarely had contacts with Caucasians until late in the 19th century. Their genes are therefore likely to be similar to those in the original Eskimo gene pool. We have compared serum concentrations of Lp(a) and apo(a) phenotypes in 78 East Greenland Eskimos (EGE) with those in Eskimos from Western Greenland (WGE) (n = 100) and Caucasian Danes (n = 466). Lp(a) levels were higher in EGE (median: 11.9 mg/dl [95% CI: 9.1-16.4]) than in Danes (p < 0.01), (median: 6.3 mg/dl [95% CI: 5.5-7.3]) and WGE (p < 0.01), (median: 7.8 mg/dl [95% CI: 5.7-10.2]). Lp(a) concentrations above 30 mg/dl were (p < 0.05) more common in EGE (19%) than in WGE (9%) and similar (p = 0.89) to those in Danes (20%). Apo(a) molecules as small as S2 or smaller (S1, B and F) were present in 26% of Danes and in 3% of WGE but were absent in EGE (p < 0.01). In contrast, a large apo(a) variant (VS4) was present in 54% of EGE and 62% of WGE, whereas it was very rare in Danes (2%). Lp(a) concentrations were inversely associated with apo(a) size in EGE (p < 0.05), WGE (p < 0.01) and Danes (p < 0.01), but EGE with S3 or S4 had significantly higher Lp(a) levels than Danes (p < 0.05) with the same phenotypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549731     DOI: 10.1007/bf01719309

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  23 in total

1.  Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis.

Authors:  C Lackner; E Boerwinkle; C C Leffert; T Rahmig; H H Hobbs
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men.

Authors:  G Sigurdsson; A Baldursdottir; H Sigvaldason; U Agnarsson; G Thorgeirsson; N Sigfusson
Journal:  Am J Cardiol       Date:  1992-05-15       Impact factor: 2.778

3.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.

Authors:  G Utermann; H J Menzel; H G Kraft; H C Duba; H G Kemmler; C Seitz
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

4.  Plasma lipoproteins: teaching old dogmas new tricks.

Authors:  M S Brown; J L Goldstein
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

5.  Lp(a) phenotyping by immunoblotting with polyclonal and monoclonal antibodies.

Authors:  H G Kraft; H Dieplinger; E Hoye; G Utermann
Journal:  Arteriosclerosis       Date:  1988 May-Jun

6.  Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication.

Authors:  J Mölgaard; I C Klausen; C Lassvik; O Faergeman; L U Gerdes; A G Olsson
Journal:  Arterioscler Thromb       Date:  1992-08

7.  Differences in apolipoprotein (a) polymorphism in west Greenland Eskimos and Caucasian Danes.

Authors:  I C Klausen; L U Gerdes; E B Schmidt; J Dyerberg; O Faergeman
Journal:  Hum Genet       Date:  1992-06       Impact factor: 4.132

8.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease.

Authors:  C Sandholzer; E Boerwinkle; N Saha; M C Tong; G Utermann
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

9.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations.

Authors:  C Sandholzer; N Saha; J D Kark; A Rees; W Jaross; H Dieplinger; F Hoppichler; E Boerwinkle; G Utermann
Journal:  Arterioscler Thromb       Date:  1992-10

10.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.

Authors:  M Jauhiainen; P Koskinen; C Ehnholm; M H Frick; M Mänttäri; V Manninen; J K Huttunen
Journal:  Atherosclerosis       Date:  1991-07       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.